Phanes Therapeutics Gains FDA Fast Track for Spevatamig
San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...
CLDN18.2
Advertisement
Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials
CHENGDU, China, July 27, 2026 Kelun-Biotech has announced that the Center for Drug Evaluation (CDE) of China’s National Medical...
AstraZeneca’s Sone-Ve Delivers Phase III Survival Breakthrough
CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...
Phanes Advances Spevatamig with Encouraging PDAC Data
SAN DIEGO, May 28, 2026 Phanes Therapeutics announced updated positive Phase 2 clinical trial results for spevatamig (PT886) in...
Ribo’s RBD1119 Moves Into Phase 2 Development for Coronary Artery Disease
SUZHOU, China, May 29, 2026 Suzhou Ribo Life Science and Ribocure Pharmaceuticals (collectively “Ribo”) have announced the submission of...
Advertisements
Antengene Expands Oncology Pipeline With Phase III ATG-022 Gastric Cancer Trial
SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...
Givastomig Phase 2 Trial Begins in Gastric Cancer
ROCKVILLE, MARYLAND, UNITED STATES — February 17, 2026 NovaBridge announced dosing of the first patient in its global, randomized...
Advertisement
